Company intelligence / Profile preview
Asklepion Pharmaceuticals
Baltimore, Maryland, United Statesasklepionpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing IV citrulline for prevention of acute lung injury in pediatric cardiopulmonary bypass patients. Phase III trial ongoing (NCT05253209). Previously investigated vaso-occlusive crisis treatment terminated in Oct-2024 due to safety concerns.
- Therapeutic areas
- HematologyPulmonologyCardiovascular
- Modalities
- Small molecules(Potential gene therapy)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
partner_name:Vanderbilt Universitytype:Research collaborationpartner_name:Seattle Children’s Hospitaltype:Clinical research
Beyond the preview
Go deeper on Asklepion Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asklepion Pharmaceuticals.